Pharmacist substitution of PBS medicines without a prescription during shortages (Serious Scarcity Substitution Instrument)

18 September 2021 - Where a Serious Scarcity Substitution Instrument has been issued by the TGA, community pharmacists can substitute specific ...

Read more →

Keytruda made available on the NHS for certain oesophageal cancer patients

17 September 2021 - NICE has recommended MSD’s Keytruda (pembrolizumab) combined with chemotherapy for the first-line treatment of certain oesophageal ...

Read more →

With remdesivir, the Federal Joint Committee assesses the additional benefit of an anti-viral COVID-19 drug for the first time

16 September 2021 - Do patients with COVID-19 have a better chance of surviving and recovering faster if they are treated ...

Read more →

Nivolumab in skin cancer: additional benefit upgraded on the basis of an indirect comparison

16 September 2021 - For nivolumab (Opdivo), the pharmaceutical company was able to achieve a significantly better result in a second ...

Read more →

BioCryst’s HAE med Orladeyo wins NICE nod

16 September 2021 - BioCryst’s Orladeyo (berotralstat) has received a positive recommendation from NICE for preventing recurrent attacks of hereditary ...

Read more →

PHARMAC funds tocilizumab to treat cases of COVID-19

16 September 2021 - PHARMAC is widening funded access to tocilizumab, an immunosuppressive drug used mainly to treat arthritis, to treat ...

Read more →

PHARMAC funds new treatment for rheumatoid arthritis to support people impacted by tocilizumab stock shortage

16 September 2021 - PHARMAC has funded upadacitinib tablets as an alternative treatment for New Zealanders with severe rheumatoid arthritis, ...

Read more →

Venetoclax in acute myeloid leukaemia: indication of a considerable added benefit

15 September 2021 - Third new area of ​​application/those affected still live a good year on average - and thus ...

Read more →

NICE backs Opdivo for head and neck cancer

15 September 2021 - NICE has recommended Bristol Myers Squibb’s (BMS) immunotherapy Opdivo (nivolumab) for routine use on the NHS ...

Read more →

Limiting the impact on Kiwis as API leaves the NZ market

14 September 2021 - PHARMAC is working hard to limit the impact on over 1 million Kiwis who currently take ...

Read more →

SMC - September 2021 decisions

13 September 2021 - The Scottish Medicines Consortium, which advises on newly licensed medicines for use by NHSScotland, has today ...

Read more →

1 October 2021 price disclosure confirmed prices

13 September 2021 - Confirmed 1 October 2021 prices resulting from the 2021 October cycle of price disclosure have now been ...

Read more →

NHS lung cancer patients in England get early access to ‘breakthrough’ cancer drug

10 September 2021 - The MHRA has approved a first-of-its-kind cancer drug – capable of targeting a gene mutation that ...

Read more →

PBAC Public Summary Documents (first time decisions not to recommend, deferrals and other matters) – May 2021 meeting

10 September 2021 - The Public Summary Documents (first time decisions not to recommend, deferrals and other matters) from the May ...

Read more →

Professor Gillian Leng to retire from NICE

9 September 2021 - Professor Leng has spent more than 20 years working at NICE. ...

Read more →